Stratification and selection of therapies to improve survival in severe alcoholic hepatitis

Table 2 Patients excluded from granulocyte colony stimulating factor therapy in randomized trial

Ref.	Intervention/control arm and inclusion criteria	Exclusion criteria	Survival at day 90
Singh et al[19] (2014)	GCSF+SOC, SMT	Upper gastrointestinal bleeding during the previous 10 days, hepatocellular carcinoma or portal vein thrombosis, hepatorenal syndrome, grade 3 or 4 hepatic encephalopathy, uncontrolled bacterial infection, human immunodeficiency virus infection, and other liver disease etiologies	18/23 (78.2%); 05/23 (21.7%)
Singh et al[18] (2018)	GCSF+SMT, SMT+GCSF+NAC, SMT	Same as above	13/19 (68.42%); 16/18 (88.8%); 6/20 (30%)
Shasthry et al[16] (2018)	GCSF, SMT	Lille score < 0.45 at day 7. Multiorgan failure	9/14 (64.2%); 4/14 (28.4%)
Tayek et al[42] (2022)	GCSF + SMT, SMT	Pregnancy, uncontrolled infection, known human immunodeficiency virus infection, recent upper gastrointestinal hemorrhage, white blood cell > 30000/mm3, creatinine > 2 mg/dL, and AH therapy for more than three days before randomization	12/16 (75%); 15/18 (83.2%)
Mishra et al[17] (2024)	GCSF, GCSF+Predni-solone, Prednisolone	Serum creatinine > 1.5 mg/dL, total leukocyte count > 25000/cmm, mDF > 90, hemoglobin of less than 10 g/dL, active infection, recent upper gastrointestinal bleeding, and the existence of any other liver disease	33/42 (78.5%); 37/42 (88.1%); 27/42 (64.2%)

GCSF: Granulocyte colony stimulating factor; SOC: Standard of care; SMT: Standard medical therapy; NAC: N-acetylcysteine.